<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250420065394N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-04-28</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The Effect of Selected training and Nano-Curcumin Supplementation on some Blood Factorsin Patients after Bariatric Surgery</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Selected training and Nano-Curcumin Supplementation on some Blood Factorsin Patients after Bariatric Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82992</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Factorial, Purpose: Basic scienece.</study_design>
      <phase>3</phase>
      <hc_freetext>Patients after Bariatric Surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group Protocol:1. Nano-curcumin Supplementation:   - Initiation: 1 month post-bariatric surgery   - Product: Sina Curcumin brand   - Dosage: 40 mg twice daily (with meals)   - Tablet specification: Each tablet contains 40 mg nano-curcumin   - Duration: 60 days2. Exercise Training:   - Frequency: 3 sessions/week   - Program duration: 60 days   - Session components:     - Warm-up     - Cool-down     - Resistance training     - Aerobic exercise   - Progressive overload:     - Week 1 intensity: 50-60% of maximum heart rate (HRmax)     - Final week intensity: 65-70% of HRmax     - Weekly increases in both duration and intensity. Intervention 2: Intervention Group Protocol:Post-bariatric surgery patients will begin nano-curcumin supplementation (Sina Curcumin brand) at 1-month postoperative, administered as:  Dosage: 40 mg twice daily (total 80 mg/day)  Formulation: 40 mg tablets (one tablet per dose)  Administration: With meals  Duration: 60 consecutive days. Intervention 3: Exercise Protocol:The selected training program will be performed three times per week for 60 days. Each session will include warm-up, cool-down, resistance training, and aerobic exercises. Training duration and intensity will progressively increase weekly, with intensity rising from 50-60% of maximum heart rate in week 1 to 65-70% of maximum heart rate in the final week. Intervention 4: Control group: No intervention takes place.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Goshtasbi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 2, 3rd Floor, Tower No. 11, Sina Complex, Iran Zamin Street, Shahrak-e Gharb, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1465896460</zip>
        <telephone>+98 21 8809 8815</telephone>
        <email>goshtasbimohammadreza@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Goshtasbi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 2, 3rd Floor, Tower No. 11, Sina Complex, Iran Zamin Street, Shahrak-e Gharb, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1465896460</zip>
        <telephone>+98 21 8809 8815</telephone>
        <email>goshtasbimohammadreza@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Obese men and women (BMI ≥30)
Absence of medically unstable hemodynamic conditions
Absence of movement disorders
No underlying conditions such as advanced pulmonary/kidney diseases, liver cirrhosis, hepatitis, or gastrointestinal disorders (e.g., celiac disease, diverticulosis)
No use of medications, tobacco, alcohol, or supplements
Completing the PRQ form for more accurate assessment of physical health in individuals</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Individuals allergic to nano-curcumin or other plants of the Zingiberaceae family
Second surgery
Use of alcohol and medications (metformin, levothyroxine, cortisone, and topiramate) within 1 month prior to the study
Unwillingness to continue participation in the study
Absence from more than three research sessions or failure to take nano-curcumin capsules more than twice
Occurrence of any health risks or complications for patients during the study protocol implementation, as confirmed by the attending physician
Age Range:30-45 years</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group Protocol:1. Nano-curcumin Supplementation:   - Initiation: 1 month post-bariatric surgery   - Product: Sina Curcumin brand   - Dosage: 40 mg twice daily (with meals)   - Tablet specification: Each tablet contains 40 mg nano-curcumin   - Duration: 60 days2. Exercise Training:   - Frequency: 3 sessions/week   - Program duration: 60 days   - Session components:     - Warm-up     - Cool-down     - Resistance training     - Aerobic exercise   - Progressive overload:     - Week 1 intensity: 50-60% of maximum heart rate (HRmax)     - Final week intensity: 65-70% of HRmax     - Weekly increases in both duration and intensity</i_keyword>
      <i_keyword>Intervention Group Protocol:Post-bariatric surgery patients will begin nano-curcumin supplementation (Sina Curcumin brand) at 1-month postoperative, administered as:  Dosage: 40 mg twice daily (total 80 mg/day)  Formulation: 40 mg tablets (one tablet per dose)  Administration: With meals  Duration: 60 consecutive days</i_keyword>
      <i_keyword>Exercise Protocol:The selected training program will be performed three times per week for 60 days. Each session will include warm-up, cool-down, resistance training, and aerobic exercises. Training duration and intensity will progressively increase weekly, with intensity rising from 50-60% of maximum heart rate in week 1 to 65-70% of maximum heart rate in the final week.</i_keyword>
      <i_keyword>Control group: No intervention takes place.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Low-density lipoprotein. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>High-density lipoprotein. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Ferritin. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Albumin. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Hemoglobin. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Alanine Aminotransferase. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Aspartate Aminotransferase. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Measurements will be performed using standard laboratory kits.</prim_outcome>
      <prim_outcome>Body fat percentage. Timepoint: Measurements will be conducted at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: Body fat percentage will be measured using the InBody 570 device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Palatable Food Craving Questionnaire - Trait (PFQ-T). Timepoint: The questionnaire will be administered at baseline (pre-intervention) and 60 days after initiating nano-curcumin supplementation and the selected training protocol. Method of measurement: The PFQ-T questionnaire will be completed by patients before and after the research protocol, with all resulting data collected.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-03-10</approval_date>
        <contact_name>Research Ethics Committees of Islamic Azad University- East Tehran Branch</contact_name>
        <contact_address>Unit 2, 3rd Floor, Tower No. 11, Sina Complex, Iran Zamin Street, Shahrak-e Gharb, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
